Chewy Stock Is Quietly Becoming a Buy Again. Here's Why.

Chewy has returned to profitability (first achieved in 2022) and reported $9.3 billion in revenue for the first nine months of fiscal 2025, up 8% year-over-year, with operating income rising to $212 million (a 74% increase from $122 million a year earlier); net income was down due to a one-time $216 million income tax benefit in 2024. Management has diversified into veterinary telehealth and pet pharmaceuticals, supporting analysts' forecasts of ~6% revenue growth this fiscal year and 8% by fiscal 2027; valuation metrics have compressed markedly (P/S down from ~7 at the 2021 peak to 0.9 today, current P/E ~55, forward P/E ~17), suggesting the stock may attract value-oriented buyers and could be poised to break out of a four-year trading range.

Analysis

Market structure: Chewy (CHWY) benefits most — repeat-consumer pet categories, pet pharmaceuticals and telehealth are high-retention, higher-margin adjacencies that should lift LTV and gross margins over 2–3 years. Amazon (AMZN) and generalist retailers face margin pressure in the pet vertical as vertical specialists capture share; expect 100–200bps annual share shift to specialists if Chewy sustains 6–8% revenue growth. Macro supply shocks (ingredient shortages) would mostly impact pet food makers and push prices, benefiting retailers with scale and inventory capability. Cross-asset: a re-rating of CHWY from P/S ~0.9 to 1.5 would attract value flows, compress equity vols and have negligible FX/commodity impact; modest tightening in corporate credit spreads if retail sentiment improves.

Risk assessment: Key tail risks include regulatory scrutiny of pet pharmaceuticals/telehealth, a renewed Amazon push into subscriptions, or a repeat of pandemic-driven demand normalization reducing active customers by >5% YoY. Near-term (days–weeks) sensitivity is to guidance and active-customer metrics; medium-term (3–12 months) to margin expansion and gross-profit per customer; long-term (12–36 months) depends on integration of pharma/telehealth and recurring-revenue penetration. Hidden dependency: recent net income benefited from a nonrecurring $216m tax item — rely on operating income and free cash flow trends, not headline EPS. Catalysts: quarterly active-customer growth, gross margin +/−200bps, and analyst upgrades within 1–3 quarters.

Trade implications: Direct play — establish a 2–3% portfolio long in CHWY scaled over 6–12 weeks, add on pullbacks >10%, target 12–36 month hold; stop-loss 20% below cost or if active customers decline YoY. Option structures — buy 12–24 month LEAP calls (ATM or 10% OTM) to express upside with defined risk, or sell 1–3 month covered calls at ~20% OTM if owning shares to fund carry. Pair trade — long CHWY (2% notional) vs short AMZN (1% notional) to hedge marketplace compression; monitor relative active-customer and gross-margin trends.

Contrarian angles: Consensus focuses on cheap multiples but underestimates execution risk on pharma/telehealth monetization; conversely, it likely underprices recurring revenue upside — a 5–10% lift in subscription penetration could re-rate forward P/E from 17 to sub-14 within 12–24 months. Historical parallel: pandemic e-commerce winners (e.g., Wayfair) re-rated only after proving repeat-purchase economics — Chewy has the advantage of reaching profitability in 2022 but must prove sustainable gross-profit per customer. Unintended consequence: an aggressive value-fund rotation into CHWY could spike stock without fundamental improvement, creating a mean-reversion shorting opportunity if margins slip.

Key Decisions for Investors

• Establish a 2–3% long position in CHWY over 6–12 weeks, average in on any >5% intraday dips; set tactical stop-loss at 20% below average cost and plan to hold 12–36 months, exiting if active customers decline YoY or gross margin falls >200bps.
• Buy 12–24 month CHWY LEAP calls (ATM or ~10% OTM) sized to 0.5–1.0% portfolio risk to capture asymmetric upside from re-rating; alternatively use a 12-month call spread (buy ATM, sell +30% OTM) to limit premium outlay.
• Implement pair trade: long CHWY (2% notional) vs short AMZN (1% notional) to hedge marketplace / macro e‑commerce risk; rebalance monthly and unwind if CHWY underperforms AMZN by >15% over a rolling 60-day window.
• If already long, sell 1–3 month covered calls ~20–25% OTM to monetize near-term premium; re-evaluate after next two quarterly reports—add to position only if revenue growth >= consensus (≥6% YoY) and operating income margin expands.
• Monitor four explicit KPIs in next 60–90 days before increasing size: active customers (target growth >0% YoY), gross profit per active customer (up yoy), operating income margin (positive trend), and analyst revisions (net upward revisions >2 consensus upgrades).